Compare MLP & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | BNTC |
|---|---|---|
| Founded | 1909 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.2M | 365.1M |
| IPO Year | 1972 | N/A |
| Metric | MLP | BNTC |
|---|---|---|
| Price | $16.12 | $13.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 38.5K | ★ 260.9K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,344,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.55 | N/A |
| 52 Week Low | $13.84 | $9.70 |
| 52 Week High | $23.41 | $17.15 |
| Indicator | MLP | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 48.76 |
| Support Level | $15.75 | $11.54 |
| Resistance Level | $16.71 | $13.68 |
| Average True Range (ATR) | 0.62 | 0.79 |
| MACD | 0.22 | 0.10 |
| Stochastic Oscillator | 82.47 | 73.44 |
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.